An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV‑2 Mpro

An Investigation of Nirmatrelvir (Paxlovid) Resistance in SARS-CoV‑2 Mpro

Saved in:

Bibliographic Details
Main Authors:	Rasha M. Yaghi, Dennis C. Wylie, Collin L. Andrews, Olivia H. Dickert, Anjana Ram, Brent L. Iverson
Format:	Article
Language:	English
Published:	American Chemical Society 2024-10-01
Series:	ACS Bio & Med Chem Au
Online Access:	https://doi.org/10.1021/acsbiomedchemau.4c00045
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Inhibitory efficacy and structural insights of Bofutrelvir against SARS-CoV-2 Mpro mutants and MERS-CoV Mpro
by: Weiwei Wang, et al.
Published: (2025-03-01)

Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus
by: Baolong Pan, et al.
Published: (2025-04-01)

Exploring Possible Drug-Resistant Variants of SARS-CoV‑2 Main Protease (Mpro) with Noncovalent Preclinical Candidate, Mpro61
by: Jessica R. Kenneson, et al.
Published: (2025-01-01)

Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: “Symptom Rebound”
by: Ashish Bhargava, et al.
Published: (2025-05-01)

Structural basis for varying drug resistance of SARS-CoV-2 Mpro E166 variants
by: Morgan A. Esler, et al.
Published: (2025-07-01)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
by: Matteo Pavan, et al.
Published: (2022-12-01)

Molecular Recognition of SARS-CoV-2 Mpro Inhibitors: Insights from Cheminformatics and Quantum Chemistry
by: Adedapo Olosunde, et al.
Published: (2025-05-01)

Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 MPro protein - an in silico and cell-based approach
by: Khushboo Singh, et al.
Published: (2025-07-01)

<i>In Silico</i> Development of SARS-CoV-2 Non-Covalent Mpro Inhibitors: A Review
by: Islam Alagawani, et al.
Published: (2025-06-01)

Computational and in vitro evaluation of sumac-derived ©Rutan compounds towards Sars-CoV-2 Mpro inhibition
by: Muzaffar Kayumov, et al.
Published: (2025-02-01)

Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses
by: Valeria Fumagalli, et al.
Published: (2023-03-01)

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
by: Rebekah Penrice-Randal, et al.
Published: (2025-05-01)

Molecular Dynamics Simulation of Ligands from Anredera cordifolia (Binahong) to the Main Protease (Mpro) of SARS-CoV-2
by: Jaka Fajar Fatriansyah, et al.
Published: (2022-01-01)

Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning
by: Anacleto Silva de Souza, et al.
Published: (2025-06-01)

Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding
by: Krishna M. Padmanabha Das, et al.
Published: (2025-07-01)

Characterization of an unusual SARS-CoV-2 main protease natural variant exhibiting resistance to nirmatrelvir and ensitrelvir
by: Dipendra Bhandari, et al.
Published: (2025-07-01)

K36-based inhibitor analogs as potential therapeutics against SARS-CoV-2 main protease (Mpro): a computational investigation
by: Mohamed L. AbouYoussef, et al.
Published: (2025-06-01)

Study of key residues in MERS-CoV and SARS-CoV-2 main proteases for resistance against clinically applied inhibitors nirmatrelvir and ensitrelvir
by: Laura Krismer, et al.
Published: (2024-06-01)

The main protease (Mpro) from SARS-CoV-2 triggers plasma clotting in vitro by activating coagulation factors VII and FXII
by: Anna Pagotto, et al.
Published: (2025-08-01)

Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (Mpro) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study
by: Trina Ekawati Tallei, et al.
Published: (2020-01-01)

A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
by: Francesco Costacurta, et al.
Published: (2024-09-01)

Synthesis and evaluation of carmofur analogs as antiproliferative agents, inhibitors to the main protease (Mpro) of SARS-CoV-2, and membrane rupture-inducing agents
by: Tiffany Gu, et al.
Published: (2025-04-01)

Effectiveness of azvudine versus nirmatrelvir/ritonavir for hospitalized patients with SARS-CoV-2 infection and pre-existing liver diseases
by: Guanyue Su, et al.
Published: (2025-05-01)

Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant
by: Sophie Marbaix, et al.
Published: (2025-02-01)

Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
by: Abhishek Bhatia, et al.
Published: (2025-01-01)

The Thiadiazole Ring (THD) Is a Building Block for Potential Inhibitors of the SARS-CoV-2 Main Protease (Mpro): Theoretical Look into the Structure, Reactivity, and Binding Profile of Three 1,3,4-THD Derivatives toward Mpro
by: Dileep Chikkur Shanthakumar, et al.
Published: (2023-12-01)

Marine-Derived Peptides from <i>Phaeodactylum tricornutum</i> as Potential SARS-CoV-2 Mpro Inhibitors: An <i>In Silico</i> Approach
by: David Mauricio Cañedo-Figueroa, et al.
Published: (2025-05-01)

IDENTIFICATION OF POTENTIAL ANTIVIRUS FROM Moringa oleifera LEAF AS MPRO SARS-COV-2 INHIBITOR: STUDY OF MOLECULAR DOCKING
by: Zaimi Afandi, et al.
Published: (2022-07-01)

Inhibitory Effects of Mangifera indica Secondary Metabolites and Their Synthetic Derivatives against SARS-CoV‑2 Mpro and NS2B/NS3 (ZIKV and DENV-2)
by: Gabriella B. Souza, et al.
Published: (2024-10-01)

Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnant Women Treated with Nirmatrelvir/Ritonavir (Paxlovid) Using Salivary Polymerase Chain Reaction: A Prospective Cohort Study
by: Chun-Han Tseng, et al.
Published: (2024-12-01)

Sintesis, Karakterisasi Struktur, dan Kajian In Silico Potensi 2'-Hidroksicalkon dan Flavonol Tersubstitusi Trimetoksi sebagai Inhibitor Main Protease (MPro) SARS-CoV-2
by: Ihsan Ikhtiarudin, et al.
Published: (2024-02-01)

Paxlovid for the treatment of severe or critical COVID-19 in children
by: Linjuan Xiang, et al.
Published: (2025-07-01)

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)
by: Ivan Gentile, et al.
Published: (2024-12-01)

Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case–control study (SAVALO Study)
by: Ivan Gentile, et al.
Published: (2025-04-01)

Magnetic Microdevices for MRI-Based Detection of SARS-CoV-2 Viruses
by: Lamar O. Mair, et al.
Published: (2020-01-01)

Paxlovid for the treatment of COVID-19: a systematic review and meta-analysis
by: Yu Wang, et al.
Published: (2024-08-01)

Mitigating Paxlovid™-induced drug‒drug interaction toxicity: an in silico insight
by: Giang H. Ta, et al.
Published: (2024-11-01)

A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.
by: Kwang Su Kim, et al.
Published: (2021-03-01)

Corrigendum to “Favipiravir vs. Deferiprone: tautomeric, photophysical, in vitro biological studies, and binding interactions with SARS-Cov-2-MPro/ACE2” [Curr. Res. Biotechnol. 7 (2024) 100176]
by: Nikolay T. Tzvetkov, et al.
Published: (2025-01-01)

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study
by: I. Gentile, et al.
Published: (2025-12-01)